Literature DB >> 26670435

Hepcidin and iron metabolism in non-diabetic obese and type 2 diabetic rats.

Yue Chen1, Hui-Qing Yin2, Hao-Ling Liu1, Lei Xiu1, Xiao-Yu Peng1.   

Abstract

The aim of this study was to investigate the changes of iron levels and hepatic regulatory molecules expression involved in iron metabolism in non-diabetic obese/type 2 diabetic rat models. Male Wistar rats were divided into 3 groups: control group, non-diabetic obese group and type 2 diabetic group (n=20 each). The rats were evaluated physiologically and biochemically. The hepatic histopathological changes were observed using haematoxylin and eosin (HE) staining. The mRNA expression patterns of hepcidin, interleukin-6 (IL-6), hypoxia-inducible factor (HIF) and ferroportin (Fpn) in the rat liver in control group, non-diabetic obese group and type 2 diabetic group were analyzed by real-time RT-PCR. The protein expression patterns of hepcidin in liver of each group were further analyzed by immunohistochemistry and Western blotting. As compared with control group, the ferritin in non-diabetic obese group and type 2 diabetic group was increased significantly (P<0.001). However, there was no significant difference in soluble transferring receptor (sTfR):ferritin ratio among the three groups (P>0.05). The real-time RT-PCR, immunohistochemistry and Western blotting results all revealed that the expression levels of hepcidin in non-diabetic obese group and type 2 diabetic group were elevated significantly as compared with those in control group (P<0.001). The expression levels of hepcidin mRNA between non-diabetic obese group and type 2 diabetic group showed no significant difference (P>0.05). However, the protein expression levels of hepcidin in type 2 diabetic group were significantly higher than those in non-diabetic obese group (P<0.05). Compared to control group, the expression levels of IL-6 mRNA in non-diabetic obese group and type 2 diabetic group were increased significantly and the expression levels of Fpn mRNA decreased (P<0.05). However, the expression levels of HIF mRNA had no significant difference among three groups. It is suggested that iron metabolism is substantially disturbed in non-diabetic obese and type 2 diabetic rats probably by the abnormal expression of hepcidin in chronic inflammatory status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of Fpn, which probably associates with the development of diabetic complication.

Entities:  

Keywords:  hepcidin; iron metabolism; non-diabetic obesity; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26670435     DOI: 10.1007/s11596-015-1517-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  27 in total

1.  Prevalence of body iron excess in the metabolic syndrome.

Authors:  Claudia Bozzini; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Antonella Bassi; Giovanna De Matteis; Ilaria Tenuti; Valentina Lotto; Simonetta Friso; Francesca Pizzolo; Roberto Corrocher
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

2.  A novel mammalian iron-regulated protein involved in intracellular iron metabolism.

Authors:  S Abboud; D J Haile
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

3.  Inflammation and iron deficiency in the hypoferremia of obesity.

Authors:  L B Yanoff; C M Menzie; B Denkinger; N G Sebring; T McHugh; A T Remaley; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2007-04-17       Impact factor: 5.095

4.  A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation.

Authors:  A T McKie; P Marciani; A Rolfs; K Brennan; K Wehr; D Barrow; S Miret; A Bomford; T J Peters; F Farzaneh; M A Hediger; M W Hentze; R J Simpson
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

5.  Status of iron, oxidant and antioxidants in chronic type 2 diabetes mellitus patients.

Authors:  H P Dulal; M Lamsal; S K Sharma; N Baral; S S Majhi
Journal:  Nepal Med Coll J       Date:  2014-09

6.  The molecular mechanism of hepcidin-mediated ferroportin down-regulation.

Authors:  Ivana De Domenico; Diane McVey Ward; Charles Langelier; Michael B Vaughn; Elizabeta Nemeth; Wesley I Sundquist; Tomas Ganz; Giovanni Musci; Jerry Kaplan
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

7.  Global estimates of the prevalence of diabetes for 2010 and 2030.

Authors:  J E Shaw; R A Sicree; P Z Zimmet
Journal:  Diabetes Res Clin Pract       Date:  2009-11-06       Impact factor: 5.602

8.  Evaluation of diagnostic efficacy of serum sTfR assay in iron-deficiency anemia and Beta-thalassemia trait in Shafa hospital, Ahvaz, Iran 2010.

Authors:  M T Jalali; A Mohseni; B Keikhaei; M Latifi
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-10       Impact factor: 3.507

9.  Late stage erythroid precursor production is impaired in mice with chronic inflammation.

Authors:  Olivier D Prince; Jacqueline M Langdon; Andrew J Layman; Ian C Prince; Miguel Sabogal; Howard H Mak; Alan E Berger; Chris Cheadle; Francis J Chrest; Qilu Yu; Nancy C Andrews; Qian-Li Xue; Curt I Civin; Jeremy D Walston; Cindy N Roy
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

Review 10.  Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Wei Bao; Ying Rong; Shuang Rong; Liegang Liu
Journal:  BMC Med       Date:  2012-10-10       Impact factor: 8.775

View more
  1 in total

1.  Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and fetal outcomes: a study protocol for a prospective cohort study.

Authors:  Gabriela Amstad Bencaiova; Deborah Ruth Vogt; Irene Hoesli
Journal:  BMJ Open       Date:  2019-11-06       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.